Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7114050 | 0.89 | PDE9A (0.44) | CSF1RLMNAPDE9ACNR1PTGS2 | |
| SCHEMBL7114058 | 0.87 | LMNA (0.36) | LMNAMEN1MAPTKMT2ACNR1 | |
| SCHEMBL7118632 | 0.82 | SIRT1 (0.44) | CSF1RLMNAMEN1MAPTKMT2A | |
| SCHEMBL7118690 | 0.81 | MEN1 (0.40) | CSF1RLMNAMEN1MAPTKMT2A | |
| SCHEMBL7116744 | 0.81 | SIRT1 (0.46) | CSF1RLMNAMEN1MAPTKMT2A | |
| SCHEMBL7124010 | 0.80 | SIRT1 (0.45) | CSF1RLMNAMEN1MAPTKMT2A | |
| SCHEMBL7114914 | 0.78 | SIRT1 (0.46) | CSF1RLMNAMEN1MAPTKMT2A | |
| SCHEMBL7118635 | 0.76 | GRIN2D (0.53) | CSF1RLMNAMEN1MAPTKMT2A | |
| SCHEMBL7552947 | 0.74 | SIRT1 (0.40) | CSF1RLMNAMEN1MAPTKMT2A | |
| SCHEMBL7121233 | 0.74 | SIRT1 (0.42) | CSF1RLMNAMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | claimed |
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | IRF3, MAVS, NQO2 | CSF1R 1831/4885LMNA 3043/4885MEN1 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.